If just 100,000 people donate $20 we can fund the cure.
We’ve built the research lab. We’ve found the doctors. They’ve set their sights on a cure. We need YOUR help to fund five clinical trials and finish the story.
For over 23 years, Dave and Lindey McIntyre have worked tirelessly to find a cure for the disease that took their Bethany. Together, they founded Bethanys Hope Foundation in 1996 shortly after their little girl was diagnosed. They refused to believe there was no hope for the disease that strikes 1 in 7,000 newborns. They took action and have never given up. Today, their passion has led to the development of a curative treatment that will change the way people like Dave and Lindey deal with the devastation of MLD. Now, there is a even more hope.
Lindey has been the Executive Director of the Foundation since 2000, managing the many demands of a fast-growing organization. Lindey continues to use her outstanding skills in interior design and event management to develop the Foundation’s many fundraising campaigns as well as a tremendous network of corporate partnerships.
Dave is a retired police officer, having served over 35 years with the Royal Canadian Mounted Police in several locations in Canada. Dave has been a full-time volunteer with the Foundation since September 2009, assisting the Foundation’s growth and campaign delivery. He is a member of the RCMP Veterans’ Association and an active member of the Knights of Columbus.
Start your donation!
Bethany’s struggle may have ended, however her legacy of hope endures and continues to inspire a community to find the answers to eliminate this wretched disease known as Metachromatic Leukodystrophy (MLD). The MLD Clinical Trials, when approved, will take place in London, Ontario at the Children’s Hospital at London Health Sciences Centre with patients from all over the globe. BethanysHope has launched the “Be on the Team for 2018” campaign, and we are counting on the generous support from ‘Team Members’ all over the world to find a cure for MLD once and for all.